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Abstract
The Wnt/b-catenin signaling pathway is important for tumor initiation and progression. The low density lipoprotein
receptor-related protein-6 (LRP6) is an essential Wnt co-receptor for Wnt/b-catenin signaling and represents a promising
anticancer target. Recently, the antihelminthic drug, niclosamide was found to inhibit Wnt/b-catenin signaling, although the
mechanism was not well defined. We found that niclosamide was able to suppress LRP6 expression and phosphorylation,
block Wnt3A-induced b-catenin accumulation, and inhibit Wnt/b-catenin signaling in HEK293 cells. Furthermore, the
inhibitory effects of niclosamide on LRP6 expression/phosphorylation and Wnt/b-catenin signaling were conformed in
human prostate PC-3 and DU145 and breast MDA-MB-231 and T-47D cancer cells. Moreover, we showed that the
mechanism by which niclosamide suppressed LRP6 resulted from increased degradation as evident by a shorter half-life.
Finally, we demonstrated that niclosamide was able to induce cancer cell apoptosis, and displayed excellent anticancer
activity with IC50 values less than 1 mM for prostate PC-3 and DU145 and breast MDA-MB-231 and T-47D cancer cells. The
IC50 values are comparable to those shown to suppress the activities of Wnt/b-catenin signaling in prostate and breast
cancer cells. Our data indicate that niclosamide is a unique small molecule Wnt/b-catenin signaling inhibitor targeting the
Wnt co-receptor LRP6 on the cell surface, and that niclosamide has a potential to be developed a novel chemopreventive or
therapeutic agent for human prostate and breast cancer.
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Introduction
Wnt/b-catenin signaling plays an important role in embryonic
development and can lead to tumor formation when aberrantly
activated. A hallmark of the Wnt/b-catenin signaling activation is
the stabilization of cytosolic b-catenin, which enters the nucleus to
activate Wnt target genes by binding transcription factors of the T-
cell factor/lymphoid enhancing factor (TCF/LEF) family [1,2]. In
the absence of Wnt ligands, b-catenin levels are efficiently
regulated by a supramolecular complex containing adenomatous
polyposis coli (APC), axin, and glycogen synthetase kinase 3b
(GSK3b). This complex promotes phosphorylation of b-catenin by
casein kinase 1 (Ck1) and GSK3b. Phosphorylated b-catenin
becomes multi-ubiquitinated (Ub) and degraded by the 26S
proteasome. The action of this complex is inhibited upon the
binding of Wnt to its receptors on the cell surface [1,2]. A variety
of Wnt/b-catenin target genes have been identified, including
those that regulate cell proliferation and apoptosis, thus mediating
cancer initiation and progression [3–5]. Compelling evidence has
indicated that there is an abnormal up-regulation of this pathway
in tumorigenesis of many types of cancer, and that disruption of
Wnt/b-catenin signaling represents a great opportunity to develop
novel drugs for cancer chemoprevention and therapy [6–8].
Experiments performed in drosophila [9], xenopus [10] and
mice [11] demonstrated that the low-density lipoprotein receptor-
related protein 5 (LRP5)/LRP6 (termed arrow in drosophila) acts
as a co-receptor for Wnt ligands, which interact with both the
seven transmembrane receptor of the Frizzled (Fz) family and
LRP5/6 to activate the canonical Wnt signaling pathway. The
cytoplasmic tails of LRP5/6, upon receptor activation by Wnt
ligand, are phosphorylated, and recruit the cytosolic scaffold
protein axin to the membrane. LRP6 is expressed in human
cancer cell lines and up-regulated in human malignant tissues
[12–16]. Studies in the past years have demonstrated that LRP6 is
a promising therapeutic target for the development of novel
anticancer drugs [6–8,15,17,18].
Niclosamide (trade name Niclocide) is a teniacide in the
antihelmintic family that is especially effective against cestodes,
which infects humans. Niclosamide has been FDA approved for
such indications and has been used in humans for nearly 50 years
[19–21]. It is believed that niclosamide inhibits oxidative
phosphorylation in the mitochondria of cestodes; an aerobic
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has been demonstrated that niclosamide can downregulate
cytosolic b-catenin expression to inhibit Wnt/b-catenin signaling
[22,23], and suppress colorectal cancer growth and metastasis
[23,24]. Since the mechanism was not well defined, we further
studied this. We demonstrated for the first time that niclosamide
can inhibit Wnt/b-catenin signaling by inducing LRP6 degrada-
tion, and that this activity is closely associated with its
antiproliferative and apoptosis inducing activity.
Results
Niclosamide blocks Wnt/b-catenin signaling induced by
Wnt3A and LRP6 by suppressing LRP6 expression in
HEK293 cells
Uncomplexed cytosolic b-catenin (free b-catenin) is the active
form of b-catenin that is translocated to the cell nucleus to activate
transcription factors of the TCF/LEF family, leading to the
transcription of Wnt target genes. To determine if niclosamide can
inhibit Wnt/b-catenin signaling, HEK293 cells were treated for
with Wnt3A conditioned medium (CM) in the presence of
niclosamide or vehicle (DMSO). The levels of cytosolic free b-
catenin and total cellular b-catenin were then examined by
Western blotting. As shown in Figure 1A, niclosamide was able to
block Wnt3A-induced cytosolic free b-catenin and total cellular b-
catenin accumulation in HEK293 cells at concentrations as low as
0.6 mM (Figure 1A).
LRP6 is an essential Wnt co-receptor for the Wnt/b-catenin
signaling pathway, and LRP6 phosphorylation is critical for Wnt/
b-catenin signaling activation induced by Wnt proteins [25–28].
To explore the molecular mechanism underlying Wnt/b-catenin
signaling inhibition by niclosamide, we examined LRP6 expres-
sion and phosphorylation after niclosamide treatment. As shown in
Figure 1A, treatment of Wnt3A CM markedly induced endoge-
nous LRP6 phosphorylation in HEK293 cells, which was
abolished by niclosamide treatment. Importantly, we also found
that the total cellular level of endogenous LRP6 was greatly
decreased after niclosamide treatment in HEK293 cells
(Figure 1A).
To confirm the inhibitory effect of niclosamide on LRP6
expression and phosphorylation, we performed a Wnt/b-catenin
signaling reporter assay to test whether niclosamide is able to
inhibit Wnt/b-catenin signal activation by LRP6 and Wnt3A.
HEK293 cells were transiently transfected with LRP6 along with
Wnt/b-catenin signaling reporter TOPFlash, and treated with
Wnt3A CM and niclosamide. As shown in Figure 1B, LRP6
expression increased the TOPFlash activity in HEK293 cells,
which was further enhanced when the cells were transfected with
LRP6 and treated with Wnt3A CM (Figure 1B). Moreover, the
increased TOPFlash activity induced by LRP6 or LRP6 plus
Wnt3A CM was blocked by niclosamide (Figure 1B).
Niclosamide suppresses LRP6 Expression and
Phosphorylation and Blocks Wnt/b-catenin Signaling in
Prostate and breast cancer cells
To determine if niclosamide can block Wnt/b-catenin signaling
in cancer cells, we examined the level of cytosolic free b-catenin
after niclosamide treatment. We found that cytosolic free b-
catenin levels in human prostate PC-3 and breast MDA-MB-231
cancer cells were significantly reduced after niclosamide treatment
(Figure 2A). Furthermore, when PC-3 and MDA-MB-231 cells
were transiently transfected with the Wnt/b-catenin signaling
reporter TOPFlash, we found that the niclosamide treatment
greatly reduced the TOPFlash activity in PC-3 and MDA-MB-231
cells (Figure. 2B).
It is well recognized that axin2 is a specific transcriptional target
of the Wnt/b-catenin signaling pathway, and that the expression
level of axin2 is the signature of the activation of Wnt/b-catenin
Figure 1. Effects of niclosamide on Wnt3A and LRP6-induced
Wnt/b signaling in HEK293 cells. (A) HEK293 cells in 6-well plates
were treated with Wnt3A CM (20%) and niclosamide at indicated
concentrations for 24 h. The levels of cytosolic free b-catenin, total
cellular b-catenin, LRP6 and phospho-LRP6 (p-LRP6) were examined. All
the samples were also probed with anti-actin antibody to verify equal
loading. (B) HEK293 cells in 24-well plates were transiently transfected
with LRP6 plasmid or the corresponding control vector, along with
TOPFlash construct and b-galactosidase-expressing vector in each well.
After being incubated for 24 h, cells were treated with niclosamide or
niclosamide plus Wnt3A CM at indicated concentrations for 24 h. The
luciferase activity was then measured 24 h later with normalization to
the activity of the b-galactosidase. Values are averages of three
determinations with the standard deviations indicated by error bars.
**P,0.01 compared to the control cells without niclosamide treatment.
doi:10.1371/journal.pone.0029290.g001
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catenin signaling, and is critical for cancer cell proliferation
[33,34]. To determine the inhibitory effects of niclosamide on
Wnt/b-catenin signaling in human cancer cells, we examined
axin2 and cyclin D1 expression in human prostate PC-3 and
DU145 and breast MDA-MB-231 and T-47D cancer cells. As
shown in Figure 3, niclosamide significantly suppressed axin2 and
cyclin D1 expression in all four cancer cell lines.
To determine if the inhibitory effect of niclosamide on Wnt/b-
catenin signaling is related to LRP6 expression, we examined
LRP6 expression and phosphorylation after niclosamide treat-
ment. As shown in Figure 3A, niclosamide was able to suppress
LRP6 expression and phosphorylation in all four cancer cell lines,
indicating that niclosamide can repress Wnt/b-catenin signaling in
breast and prostate cancer cells by suppressing LRP6 expression.
Niclosamide Induces LRP6 Degradation
To define the molecular mechanism underlying the effect of
niclosamide on LRP6 protein level, we studied LRP6 turnover.
PC-3 cells were treated with niclosamide at 1.2 mM for 0, 3, 6, 10
and 24 h in the presence of cycloheximide, a protein synthesis
inhibitor. As shown in Figure 4, in the absence of niclosamide
treatment, LRP6 was degraded with a half-life of about 6.9 h.
Treatment with niclosamide significantly enhanced LRP6 turn-
over with a half-life of about 2.3 h (Figure 4A). This shortening of
LRP6 half-life suggests that niclosamide can stimulate LRP6
degradation. To test whether niclosamide regulates LRP6
expression at the transcription level too, we examined LRP6
mRNA levels by real-time RT-PCR. As shown in Figure 4B,
LRP6 mRNA levels were not significantly changed after
niclosamide treatment in PC-3 and MDA-MB-231 cells. There-
fore, niclosamide-induced LRP6 suppression is mainly due to the
enhanced LRP6 degradation.
Niclosamide Has No Effect on Dishevelled-2 (Dvl2)
Expression in Prostate and Breast Cancer Cells
It has been reported that niclosamide downregulates compo-
nents of the Wnt pathway, specifically cytosolic Dvl2 expression,
resulting in diminished downstream Wnt/b-catenin signaling in
colorectal cancers [23]. To test whether Dvl2 is also involved in
niclosamide-induced Wnt/b-catenin signaling inhibition in pros-
tate and breast cancer cells, we examined both total cellular and
cytosolic levels of Dvl2 expression. Unexpectedly, we found that
niclosamide had no effect on both total cellular and cytosolic Dvl2
expression in human prostate PC-3 and DU145 and breast MDA-
MB-231 and T-47D cancer cells (Figure 3), while LRP6 expression
was greatly suppressed at the same treatment (Figure 3A). These
results indicate that LRP6 downregulation is the key mechanism
underlying niclosamide-induced Wnt/b-catenin signaling inhibi-
tion in human prostate PC-3 and DU145 and breast MDA-MB-
231 and T-47D cancer cells.
Niclosamide Induces Prostate and Breast Cancer Cell
Apoptosis and Inhibits Cancer Cell Proliferation
The Wnt/b-catenin pathway is important for cancer cell
apoptosis [35,36]. Having established that niclosamide is a potent
inhibitor of Wnt/b-catenin signaling in prostate and breast cancer
cells, we then tested whether niclosamide is able to induce
apoptosis. As shown in Figure 5A, exposure to niclosamide at 1.2
and 2.4 mM for 24 h significantly induced apoptotic DNA
fragmentation in prostate PC-3 and DU145 and breast MDA-
MB-231 and T-47D cancer cells.
Given that niclosamide can block Wnt/b-catenin signaling in
cancer cells and can induce apoptosis, we next examined the effect
of niclosamide on cancer cell proliferation. As shown in Figure 5B,
niclosamide inhibited cancer cell proliferation with IC50 values less
than 1 mM for all four tested cell lines. The IC50 values are
comparable to those shown to suppress the activities of Wnt/b-
catenin signaling in prostate and breast cancer cells.
Discussion
Compelling evidence indicates that there is an abnormal up-
regulation of the Wnt/b-catenin pathway in tumorigenesis of
many types of cancer. While genetic mutations of certain
components of the Wnt/b-catenin pathway, such as APC and
CTNNB1, are significant contributing factors for colorectal
cancers, they are typically not the predominate mechanism
associated with many other types of cancer such as breast and
prostate cancers. Instead, it appears that dysregulation of Wnt/b-
catenin signaling on the cell surface leads to aberrant activation of
this pathway in these types of cancer [3–5,37]. Therefore, targeted
inhibition of Wnt/b-catenin signaling at the cell surface is a
rational and promising new approach for the cancer therapy.
Figure 2. Effects of niclosamide on Wnt/b-catenin signaling in
cancer cells. (A) Prostate cancer PC-3 and breast cancer MDA-MB-231
cells in 6-well plates were treated with niclosamide at the indicated
concentrations for 24 h. The levels of cytosolic free b-catenin were then
examined by GST-E-cadherin binding assay. (B) Prostate cancer PC-3
and breast cancer MDA-MB-231 cells in 24-well plates were transiently
transfected with the TOPFlash luciferase construct and b-galactosidase-
expressing vector in each well. After 24 h incubation, cells were treated
with 2.4 mM niclosamide. The luciferase activity was then measured
24 h later with normalization to the activity of the b-galactosidase.
Values are the average of triple determinations with the s.d. indicated
by error bars. **P,0.01 compared to the control cells.
doi:10.1371/journal.pone.0029290.g002
Niclosamide Is a LRP6 Inhibitor
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e29290Figure 3. Effects of niclosamide on expression of LRP6, phosph-LRP6 (p-LRP6), Dvl2, Axin2 and Cyclin D1 in cancer cells. (A) DU145
and PC3 prostate cancer cells and MDA-MB-231 and T-47D breast cancer cells in 6-well plates were treated with niclosamide at indicated
concentrations for 24 h. The total cellular levels of LRP6, p-LRP6, Dvl2, Axin2 and Cyclin D1were then examined. All the samples were also probed
with anti-actin antibody to verify equal loading. (B) PC-3 and DU145 prostate cancer cells and MDA-MB-231 and T-47D breast cancer cells in 6-well
plates were treated with niclosamide at indicated concentrations for 24 h. The cytosolic levels of Dvl2 were then examined. All the samples were also
probed with anti-actin antibody to verify equal loading.
doi:10.1371/journal.pone.0029290.g003
Figure 4. Effects of niclosamide on LRP6 expression and degradation. (A) PC-3 cells were incubated with 10 mg/ml of cycloheximide in the
presence of Niclosamide (1.2 mM) or vehicle for 0, 3, 6, 10 or 24 h. Cells were then harvested, and the level of endogenous LRP6 was examined by
Western blotting. Samples were also probed with anti-actin antibody to verify equal loading. The pixels for each band were measured, normalized
and plotted. Data are mean values of three independent experiments with the SD values indicated by error bars. *P,0.05, **P,0.01 versus
corresponding control value. (B) PC-3 and MDA-MB-231 cells in 6-well plates were treated with niclosamide for 24 h. The cells were then harvested
and LRP6 mRNA levels were determined by real-time RT-PCR and normalized to the message levels of GAPDH mRNA. All the values are the average of
triple determinations with the s.d. indicated by error bars.
doi:10.1371/journal.pone.0029290.g004
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gland development and carcinogenesis [4]. Triple negative breast
cancer (TNBC; ER, PR, and HER2-negative breast cancer) is one
of the most difficult subtypes of breast cancer to treat due to a lack
of a targeted therapy. Studies have demonstrated that Wnt/b-
catenin signaling activation is preferentially found in TNBC and is
associated with a poor clinical outcome [38]. Basal-like breast
cancer (BLBC) shares many overlapping features with BLBC.
Several studies have demonstrated that LRP6 is up-regulated in
human TNBC or BLBC [14–16]. In mice, mammary gland
development and MMTV-Wnt1-induced mammary tumorigene-
sis were delayed in LRP6
+/- mice [14], while MMTV-LRP6
transgenic mice developed hyperplasia in their mammary glands
due to LRP6-mediated Wnt/b-catenin signaling [39]. Transcrip-
tional knockdown of LRP6 in TNBC MDA-MB-231 cells
significantly decreased Wnt/b-catenin signaling, cell proliferation,
and tumor growth in vivo [15]. In addition, it has been
demonstrated that specific LRP6 antibodies were able to block
MMTV-Wnt1 or MMTV-Wnt3 xenografts in vivo [17,18], and
that recombinant Mesd protein, an LRP6 antagonist, markedly
suppressed tumor growth in MMTV-Wnt1 xenograft models [15].
Moreover, salinomycin, a breast cancer stem cell killer [40], was
recently demonstrated to be an inhibitor of Wnt/b-catenin
signaling by inducing LRP6 degradation [41]. In the present
study, we demonstrated that niclosamide suppressed LRP6
expression in TNBC MDA-MB-231 cells and ER-positive breast
cancer T-47D cells, and inhibited breast cancer cell proliferation
with IC50 values less than 1 mM. Our results support the concept
that LRP6 is a promising therapeutic target for breast cancer
including TNBC.
Accumulated evidence has demonstrated a significant role for
Wnt/b-catenin signaling in the development and progression of
human prostate cancer [3]. Although it is unclear whether LRP6 is
up-regulated in prostate cancer, we have recently demonstrated
that the LRP6 antagonist Mesd markedly inhibited Wnt/b-catenin
signaling in prostate cancer PC-3 cells, and suppressed PC-3 cell
proliferation in vitro and tumor growth in vivo [42,43]. In the
present study, we found niclosamide inhibited the proliferation of
prostate cancer PC-3 and DU145 cells with IC50 values less than
1 mM, which are comparable to those shown to suppress LRP6
expression and the activities of Wnt/b-catenin signaling in
prostate cancer cells. Together, these findings suggest that LRP6
is a potential therapeutic target for prostate cancer.
Mutations in APC and CTNNB1 are two major factors for Wnt/
b-catenin signaling activation in colorectal cancers, however
recent studies indicate that the levels of Wnt/b-catenin signaling
in colorectal cancer cells could be modulated on the cell surface
[44–48]. In particular, Ueno et al. demonstrated that Wnt receptor
frizzled-7 activates the Wnt/b-catenin pathway in colorectal
cancer cells despite the presence of APC or CTNNB1 mutation
and that frizzled-7-siRNA may be used as a therapeutic reagent
for colorectal cancer [48]. Shi et al. reported that siRNA silencing
Figure 5. Effects of niclosamide on cancer cell apoptosis and proliferation. (A) Cancer cells were treated with niclosamide at the indicated
concentrations for 24 h. Floating and attached cells were combined for apoptosis detection by the Cell Death ELISA kit from Roche Diagnostics
Corporation for histone-associated DNA fragments as described in Materials and Methods. (B) Cancer cells in 96-well plates were treated with
niclosamide for 72 h. Cell viability was measured by the Cell Titer Glo Assay system. All the values are the average of triplicate determinations with
the s.d. indicated by error bars. **P,0.01 versus corresponding control value.
doi:10.1371/journal.pone.0029290.g005
Niclosamide Is a LRP6 Inhibitor
PLoS ONE | www.plosone.org 5 December 2011 | Volume 6 | Issue 12 | e29290of Wnt-2, which is well known for its overexpression in colorectal
cancer, inhibited Wnt/b-catenin signaling and induced apoptosis
in human colorectal cancer cells containing downstream
mutations [47]. The secreted frizzled-related protein (SFRP)
family and Wnt inhibitory factor-1 (WIF-1) are secreted Wnt/b-
catenin signaling antagonists that bind to Wnt ligands, and
interfere with Wnt-receptor interaction. It has been reported that
loss of SFRP family expression was associated with promoter
hypermethylation in colorectal cancer [44], and that restoration
of SFRP function in colorectal cancer cells attenuates Wnt/b-
catenin signaling even in the presence of downstream mutations
[45]. Similarly, He et al. reported that loss of WIF-1 expression
was associated with promoter hypermethylation in colorectal
cancer, and that restoration of WIF-1 function, Wnt-1 siRNA, or
a monoclonal anti-Wnt-1 antibody induces significant apoptosis
in colorectal cancer cells which contain downstream mutations
and expressing Wnt-1 [46]. Very recently, it has been reported
that niclosamide was able to inhibit Wnt/b-catenin signaling in
colorectal cancer cells, inhibited colorectal cancer growth and
S100A4-mediated metastatic colorectal cancer [23,24]. The
calcium-binding protein S100A4 is a target gene of the Wnt/b-
catenin pathway [49]. Future studies are required to address the
importance of LRP6 in colorectal cancer development and
progression.
The development of FDA approved drugs that are used for
other indications is an attractive strategy for developing new
drugs for cancer chemoprevention or therapy given their proven
safety record. Disruption of Wnt/b-catenin signaling represents a
great opportunity to determine if FDA approved drugs might
have potential anticancer efficacy [6–8]. Niclosamide is a
salicyclamide derivative and the drug of choice for the treatment
of most tapeworm infection. Niclosamide exerts its antiparasitic
activity in the intestinal lumen and is poorly absorbed from the
gastrointestinal tract [19–21]. However, in mice implanted with
human colorectal cancer xenografts, orally administered niclosa-
mide was well tolerated, achieved plasma and tumor levels
associated with biologic activity and led to tumor control [23].
Furthermore, niclosamide has no significant toxicity against non-
cancer cells in vitro and displays no obvious side effects in
niclosamide-treated mice [23]. We demonstrate herein that
niclosamide is a potent Wnt/b-catenin signaling inhibitor by
inducing LRP6 degradation in cancer cells, and displays an
excellent anticancer activity in vitro. Therefore, as a FDA
approved antihelminthic drug, niclosamide will be an interesting
comoound to be optimized to increase its bioavailability and to be
tested for its in vivo cancer preventive and therapeutic roles in the
future.
Materials and Methods
Materials
Niclosamide was purchased from Sigma. Polyclonal anti-
phospho-LRP6 (Ser1490) and anti-Dvl2 and monoclonal anti-
Axin2 were purchased from Cell Signaling Technology. Mono-
clonal anti-LRP6 was from Santa Cruz Biotechnology. Polyclonal
rabbit anti-Cyclin D1 was from Chemicon International. Mono-
clonal anti-b-catenin was from BD Biosciences. Monoclonal anti-
actin was from Sigma. Peroxidase labeled anti-mouse antibody
and ECL system were purchased from Amersham Life Science.
Plasmid pCS-Myc-hLRP6 containing the full-length human LRP6
cDNA was from Dr. Christof Niehrs (Deutsches Krebsforschungs-
zentrum, Heidelberg, Germany). Plasmid Glutathione S-transfer-
ase (GST)-E-cadherin was kindly provided by Dr. Gail Johnson
(University of Rochester, NY). The TOPFlash luciferase construct
was from Upstate Biotechnology. The b-galactosidase-expressing
vector, the luciferase assay system and the b-galactosidase assay
system were purchased from Promega. Tissue culture media, fetal
bovine serum (FBS), and plastic-ware were obtained from Life
Technologies, Inc. Proteinase inhibitor cocktail Complete
TM was
obtained from Boehringer Mannheim. All cell lines were obtained
from ATCC and were cultured in RPMI-1640 medium containing
10% fetal bovine serum, 2 mM of L-glutamine, 100 units/ml of
penicillin, and 100 mg/ml of streptomycin. Cells were grown in
antibiotic-free medium for cell proliferation assays. Cell Titer Glo
assay systems were from Promega. Cell death detection ELISA kit
was purchased from Roche Diagnostics Corporation.
Western blotting
Cells in 6-well plates were lysed in 0.5 ml of lysis buffer
(phosphate-buffered saline containing 1% Triton X-100 and
1 mM PMSF) at 4uC for 10 min. Equal quantities of protein
were subjected to SDS-PAGE under reducing conditions.
Following transfer to immobilon-P transfer membrane, successive
incubations with a primary antibody, and a horseradish peroxi-
dase-conjugated secondary antibody were carried out for 60–
120 min at room temperature. The immunoreactive proteins were
then detected using the ECL system. Films showing immunore-
active bands were scanned by Hp Scanjet 5590.
Cytosolic free b-catenin analysis with GST-E-cadherin
binding assay
The GST-E-cadherin binding assay was carried out exactly as
previously described [50]. Uncomplexed cytosolic free b-catenin
present in 100 mg of total cell lysate was subjected to SDS-PAGE
and detected using the monoclonal antibody to b-catenin.
Real-time RT-PCR
Total RNA was isolated from cell cultures using RNA-Bee (Tel-
Test), and first-strand cDNA synthesis was performed using
ProSTARTM Ultro HF RT-PCR Kit (Strategene) primed with
oligo(dT) primer in a 20 ml reaction mixture containing 1 mg total
RNA. For analysis of LRP6 mRNA levels, real-time RT-PCR was
performed with the specific LRP6 and GAPDH primers
purchased from SABioscience/Qiagene. The LRP6 mRNA level
was normalized to the GAPDH mRNA level.
Analysisof cytosolic Dvl2 expression
Cytosolic Dvl2 expression was examined with the method as
described for elsewhere [23]. Briefly, cells were lysed with
hypotonic lysis buffer (consisting of 10 mM Tris-HCl, pH 7.4
and 0.2 mM MgCl2, supplemented with protease inhibitors,
incubated on ice for 10 min, and homogenized using a tight-fitting
glass dounce. Sucrose and EDTA were added to final concentra-
tions of 0.25 M and 1 mM, respectively. Lysates were then
centrifuged at 20,0006g for 1 h at 4uC. Supernatant representing
cytosolic cell fraction was then diluted into SDS sample buffer, and
Dvl2 expression was then examined by Western blotting.
Luciferase reporter assay
Cancer cells were plated into 24-well plates. After overnight
culture, the cells were transiently transfected with 0.1 mg of the
TOPFlash luciferase construct (Upstate Biotechnology) and 0.1 mg
of b-galactosidase-expressing vector (Promega, Madison, WI).
After 24 h incubation, cells were treated with niclosamide. Cells
were then lysed 24 h later and both luciferase and b-galactosidase
activities were determined. The luciferase activity was normalized
to the b-galactosidase activity.
Niclosamide Is a LRP6 Inhibitor
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Apoptosis was assessed with cell death detection ELISA kit
purchased from Roche Diagnostics Corporation, Indianapolis.
This assay detects oligonucleosomes released after gentle lysis of
the cell. Cells were cultured in T25 flasks for the desired duration.
The spent medium containing floating cells was saved and kept on
ice. The adherent cells were collected by gentle trypsinization and
were combined with the floaters for pelleting by centrifugation.
After gentle lysis of the cells with the buffer provided with the
detection kit, the cell lysate was used for the ELISA test. The
results were normalized by the protein content obtained from
parallel flasks with the cells being lysed using the buffer as
described above for Western blotting.
Cell proliferation assay
Cells were seeded into 96-well tissue culture treated microtiter
plates at a density of 5000 cells/well in a total volume of 50 ml.
After overnight incubation, the cells were treated with niclosamide
for 72 h by adding 50 ml of 2X stock solutions to appropriate wells
already containing 50 ml of cells and medium to expose cells to the
final concentrations of niclosamide required. Cell viability was
measured by the Cell Titer Glo Assay (Promega).
Statistics
Statistical analyses were performed using Student’s unpaired t-
test. Data were presented as mean 6 SD. Differences at P,0.05
were considered statistically significant.
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